ABT — ABBOTT LABORATORIES
Health Care
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ABT?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 5 tracked investors who changed their ABT position last quarter, 1 bought and 4 sold (20% buy-side). Macro conditions are a headwind for Health Care (Macro Tailwind 36/100 in a Expansion regime). 2 congressional purchases, 2 sales disclosed in the last 6 months.
- +1 tracked investor added or increased positions last quarter (Steve Cohen)
- +5 tracked investors reported holding ABT at their latest filing
- +2 congressional purchases disclosed in the last 6 months
- −4 tracked investors reduced or exited last quarter (4 reduced, 0 sold out)
- −Current Expansion regime has historically been a headwind for Health Care (Macro Tailwind 36/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT) appears in the most recent 13F filings of 5 tracked institutional investors. ABBOTT LABORATORIES is classified in the Health Care sector. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.1B. Across recent filings, tracked investors recorded 7 new positions, 15 increased, 25 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ABT
How many top investors track ABT
A small number of top investors own this.
ABT Ownership Composition
How ABBOTT LABORATORIES is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant97.2%
- Macro2.8%
Tracked investors currently reporting ABT
1 tracked investor has since exited this position — listed separately below.
- Ken GriffinSep 30, 2026Citadel AdvisorsShares5.3MValue$520.7M% Portfolio0.06%
- Izzy EnglanderSep 30, 2026Millennium ManagementShares3.2MValue$316.4M% Portfolio0.10%
- Steve CohenSep 30, 2026Point72 Asset ManagementShares2.4MValue$239.2M% Portfolio0.27%
- Ray DalioSep 30, 2026Bridgewater AssociatesShares55.8KValue$5.5M% Portfolio0.02%
- Paul Tudor JonesSep 30, 2026Tudor Investment CorpShares260.3KValue$25.7M% Portfolio0.03%
Previously held ABT
These investors reported ABT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| George Soros | Soros Fund Management | 44.8K | $4.6M | Mar 31, 2026 |
Recent activity
- Reduced$25.7M(-75.44%)Nov 16, 2026
- Reduced$316.4M(-27.32%)Nov 16, 2026
- Increased$239.2M(40.05%)Nov 16, 2026
- Reduced$520.7M(-56.34%)Nov 16, 2026
- Reduced$5.5M(-6.67%)Nov 16, 2026
- Unchanged$4.4M(0.00%)Nov 13, 2026
- Reduced$345.2M(-12.45%)Nov 14, 2024
- Reduced$162.4M(-52.59%)Feb 14, 2025
- Increased$341M(79.07%)May 15, 2025
- Reduced$191.8M(-45.15%)Aug 14, 2025
- Increased$282.2M(24.01%)Feb 17, 2026
- Reduced$193.7M(-16.22%)May 15, 2026
- Increased$399.8M(133.47%)Aug 14, 2026
- New$4.6MMay 15, 2026
- Unchanged$4.1M(0.00%)Aug 14, 2026
- Reduced$369.2M(-35.91%)Nov 14, 2024
- Reduced$381M(-42.58%)May 15, 2025
- Increased$416.4M(6.59%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Increased$1.1B(215.87%)Aug 14, 2026
- Reduced$208.8M(-8.54%)Feb 14, 2024
- Reduced$197.3M(-8.49%)May 14, 2024
- Reduced$173.4M(-3.90%)Aug 14, 2024
- Reduced$80.7M(-57.59%)Nov 13, 2024
- Reduced$21.7M(-72.91%)Feb 13, 2025
- Reduced$9.7M(-62.01%)May 14, 2025
- Reduced$7.7M(-21.89%)Aug 13, 2025
- Sold$0(-100.00%)Nov 13, 2025
- New$12MMay 15, 2026
- Reduced$5.4M(-48.93%)Aug 14, 2026
- Increased$22.3M(292.96%)Nov 14, 2024
- Increased$26.4M(19.46%)Feb 14, 2025
- Reduced$18.6M(-39.91%)Jul 21, 2025
- Reduced$612K(-96.79%)Aug 14, 2025
- Increased$803.6K(33.33%)Nov 14, 2025
- Increased$51.7M(6773.33%)Feb 17, 2026
- Reduced$31.3M(-26.09%)May 15, 2026
- Increased$156.8M(467.00%)Aug 14, 2026
- Reduced$25.3M(-57.50%)Aug 14, 2024
- Reduced$18.4M(-33.63%)Nov 14, 2024
- Reduced$4.1M(-77.70%)Feb 14, 2025
- Reduced$4.7M(-1.67%)May 15, 2025
- Increased$8.9M(85.31%)Aug 14, 2025
- Increased$12.9M(46.80%)Dec 9, 2025
- Increased$62.6M(198.12%)May 15, 2026
- Increased$96.2M(73.69%)Aug 14, 2026
- New$200.9MNov 13, 2023
- New$5.2MSep 16, 2024
- New$525MAug 14, 2024
- $260.8MMay 15, 2024
- $65.1MMay 15, 2024
Frequently asked questions
- How many institutional investors hold ABT?
- 5 tracked institutional investors disclosed a position in ABT (ABBOTT LABORATORIES) in their most recent 13F filing.
- Who is the largest institutional holder of ABT?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ABT, valued at $1.1B.
- Did institutional ownership of ABT increase or decrease?
- Across recent 13F filings, tracked investors recorded 7 new positions, 15 increased, 25 reduced, and 2 fully exited ABT.
- What sector is ABT in?
- ABBOTT LABORATORIES is classified in the Health Care GICS sector.
- Where does this ABT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.